The aim of this study was to compare the effects of 3 inhalation agents that combined with dexmedetomidine infusion on hemodynamic stability and postoperative recovery in patients undergoing supratentorial tumor surgery. After the institute's ethics committee approved this study and written informed consent was obtained from each participant, 90 patients with ASA I and III, who were scheduled for supratentorial tumor surgery, were recruited for this prospective, randomized controlled study. Routine monitoring was applied for unpremedicated patients on arrival in the operating room. All the patients received IV dexmedetomidine 0.5 mg/kg over 10 minutes, followed by 0.9 mg/kg/h infusion during maintenance. Patients were randomly divided into 3 groups. Anesthesia was maintained by sevoflurane in group 1, desflurane in group 2, and isoflurane in group 3. Hemodynamic variables, brain relaxation scores, intraoperative anesthetics requirement, and recovery characteristics were recorded. Demographic values, hemodynamic variables, and brain relaxation scores were similar among the groups. Mean arterial pressure was higher after intubation at the first minute in all groups than at baseline values. Hypertension was reported in 4 of 30 patients in group 1, 8 of 30 patients in group 2, and 5 of 30 patients in group 3, intraoperatively. Eye opening, following the verbal commands, was significantly lesser in patients receiving desflurane-dexmedetomidine than the other groups (P = 0.001). We conclude that dexmedetomidine infusion is not sufficient for suppressing hemodynamic responses, decreasing the requirement of inhalation agents, and providing adequate brain relaxation in patients undergoing supratentorial craniotomy. Desflurane-dexmedetomidine anesthesia offers lesser eye opening and a slower response to verbal commands postoperatively.
T he ideal characteristics of anesthetic agents used in neurosurgery are maintenance of coupling between cerebral blood flow and metabolism, intact cerebrovascular autoregulation, no increase in cerebral blood volume or intracranial pressure, neuroprotection, and anticonvulsive potential. Volatile anesthetics have a dual effect on cerebral vasculature. At low concentrations, halothane, isoflurane, and sevoflurane constrict cerebral vessels secondary to suppression of metabolism. 1 With increasing concentration the direct vasodilative effect of volatile anesthetics turns dominant, leading to high cerebral blood flow and volume and to elevated intracranial pressure. Isoflurane and sevoflurane (1.0 MAC) are less vasoactive, with sevoflurane exhibiting only minimal vasoactivity. 2 Dexmedetomidine is a highly selective a-2 agonist that has an 8 times greater affinity for the a-2 receptor than clonidine. It is 1620 times more potent as an a-2 agonist than an a-1 agonist. It is also slower acting than clonidine. This characteristic allows for ready titration as an intravenous infusion for sedation. [3] [4] [5] In comparison with the ideal sedative/analgesic, dexmedetomidine lacks a potentially toxic injection vehicle, does not seem to affect white blood cell function, has minimal to no depressant effect on adrenal steroidogenesis, and is not associated with the development of tolerance. In addition, it has been proposed to be neuroprotective. 6 Dexmedetomidine has been reported as an adjunct to either regional or general anesthesia.
Alpha-2 agonists have little effect on intracranial pressure 7, 8 and direct activation of cerebral a-2b receptors may result in cerebral vasoconstriction (and perhaps more importantly, venoconstriction). As dexmedetomidine provides good perioperative hemodynamic stability with decreased intraoperative opioid requirements, it might be a suitable anesthetic adjuvant to neurosurgical anaesthesia. [9] [10] [11] [12] [13] [14] In this study, we compared the hemodynamic stability, anesthetics requirements, brain relaxation, and recovery characteristics of sevoflurane, desflurane, or isoflurane anesthesia supplemented with an infusion of dexmedetomidine in patients undergoing supratentorial craniotomy.
MATERIALS AND METHODS
After obtaining the approval of the institute's ethics committee and written informed consent, 90 patients undergoing supratentorial craniotomy for space-occupying lesion surgery were recruited. The exclusion criteria were as follows: pregnant or nursing women or premenopausal women without reliable contraception; morbid obesity; preoperative heart rate (HR) <45 beats/min; second-or third-degree AV block; antihypertensive medication with a-methyldopa, clonidine, or other a2adrenergic agonist; and participation in another drug study during the preceding 1-month period. On the day before surgery, all patients visited the hospital for preanesthesia assessment for explaining the study protocol and use of the anesthetic or analgesic techniques.
On arrival in the operating room, routine monitors were applied to the unpremedicated patients for recording HR, invasive (radial artery) systolic (SAP), diastolic (DAP), and mean arterial pressure (MAP), peripheral oxygen saturation (SpO 2 ), and urine output (bladder catheter). Baseline hemodynamic data were taken from preoperative measurements.
All patients received 0.9% NaCl, 2 to 3 mL/kg before induction into the study. All of the patients received IV dexmedetomidine (0.5 mg/kg) over 10 minutes, followed by a 0.9 mg/kg/h infusion during maintenance. Patients were randomly allocated to 3 groups. Anesthesia was induced with a sleep dose of sodium thiopental (3 to 5 mg/kg) and neuromuscular blockade was obtained with vecuronium (0.1 mg/kg). After tracheal intubation, the lungs were ventilated with an N 2 O/oxygen mixture (FiO 2 0.5) and anesthesia was maintained with a constant infusion of dexmedetomidine (0.9 mg/kg/h) supplemented with either sevoflurane (group 1), desflurane (group 2), or isoflurane (group 3). Throughout the study period, the concentration of the volatile anesthetic was recorded.
All patients were mechanically ventilated to maintain the end-tidal CO 2 concentration in the range of 30 to 35 mm Hg. The targeted range of MAP values was 60 to 100 mm Hg. Hemodynamic variables at baseline, induction of anesthesia, tracheal intubation, skin incision, dural incision, and dural closure were recorded. The following autonomic responses were considered indicative of a ''depth of anesthesia''; (1) increase in MAP >100 mm Hg for >1 minute, (2) increase in HR >25% above baseline or 90 bpm for >1 minute, and (3) somatic signs (eg, purposeful movements, swallowing, or grimacing) and autonomic signs.
As required, light anesthesia responses to the concentration of anesthetic agents (maximum 1 MAC) were adjusted, but the rate of dexmedetomidine infusion was unchanged. If primary hypotension was treated with fluid administration (saline or HES 130,000/0.4; Voluven), then hypotension was controlled by a decreased concentration of inhalation agents (25% to 50%). If MAP did not exceed 60 mm Hg within 2 minutes, IV ephedrine (5 to 10 mg) was administered.
Brain relaxation scores during craniotomy were evaluated by neurosurgeons (1 point = good, 5 point = worse). 15 All patients received a standardized dose of IV tramadol (2 mg/kg) and IM diclofenac sodium (75 mg). Dexmedetomidine infusion was continued in the 3 groups until the start of skin closure. Then, sevoflurane, desflurane, or isoflurane were discontinued at the completion of closure skin (approximately in the last 5 min). After completion of the surgery, neuromuscular blockade was reversed with atropine (0.02 mg/kg) and neostigmine (0.04 mg/kg). Extubation was carried out when patients responded to verbal commands and were breathing spontaneously. The time to extubation was recorded. Then, patients were transferred to the postanesthesia care unit (PACU). The patients remained in the recovery room for 45 minutes while SAP, HR, SpO 2 , and respiratory rate were observed. Anesthetic recovery was assessed by the level of consciousness, eye opening, and the ability to follow verbal commands. Postoperative nausea and vomiting, headache, and any changes in the neurologic status were recorded.
Pain was assessed using the Visual Analog Scale 5, 10, 15, 30, and 45 minutes after extubation and 1, 2, 4, 6, 12, 24 hours. The Visual Analog Scale score was 6 or greater and clinical assessment was consistent with a diagnosis of pain, and rescue medication was administered (diclofenac sodium 75 mg IM). The number of patients who required rescue analgesic was indicated.
Qualitative data were analyzed with Pearson w 2 . Quantitative data, expressed as mean SD or SEM, were analyzed by analysis of variance test. A probability value P<0.05 was considered statistically significant. All analyses were calculated by using SPSS 10.0 (SPSS, Chicago, IL).
RESULTS
Demographic values for the groups were similar ( Table 1) . Preexisting medical conditions, including hypertension, and neurologic conditions (level of consciousness, reflexes, neurologic status), and type of neurosurgical procedure, were similar in the 3 groups. All patients underwent craniotomy for the supratentorial space-occupying lesion.
No significant difference was found in systolic, diastolic, and MAP, throughout the study period among the groups (P>0.05). In all the groups, clinical SAP was significantly lower than in the baseline measures during the induction, after intubation at 3 and 5 minutes, and during skin incision, dural incision, and dural closure. Diastolic blood pressure showed an initial decrease from baseline values except after the intubation at 1 minute. MAP values were higher after intubation at 1 minute in all groups than baseline values or other measures ( Table 2) . Hypertension was reported in 4 of 30 patients in the sevoflurane-dexmedetomidine group and in 8 of 30 patients in the desflurane-dexmedetomidine group and 5 of 30 patients in the isoflurane-dexmedetomidine group and required an increasing concentration of inhalation agents. There was no need for the administration of vasodilator agents in hypertensive patients (P>0.05).
MAP values of <60 mm Hg were easily controlled by increasing fluid administration and/or by reducing the concentration of sevoflurane, desflurane, and isoflurane. There was no need for the administration of vasopressor agents in the 3 groups (P>0.05). Two of 30 patients in the sevoflurane-dexmedetomidine group and 1 of 30 patients in the desflurane-dexmedetomidine group required fluid administration and decreasing concentration of inhalation agents ( Table 2 ).
No significant difference was found among the groups with respect to HR during the study period. HR values were significantly higher than in the baseline measures during induction, after intubation at 1 and 3 minutes, and after the skin incision. No patient experienced intraoperative bradycardia (Table 3 ).
Brain relaxation scores were similar among the groups intraoperatively (P>0.05) ( Table 4 ). The concentration of inhalation anesthetics was reduced throughout the study period with the infusion of dexmedetomidine in all groups (Table 5 ).
Time to extubation was similar postdiscontinuation of anesthesia in all patients (P>0.05). Median time to extubation was 7.6 minutes for the sevofluranedexmedetomidine group and 4.5 minutes for the desfluranedexmedetomidine group and 5.8 minutes for the isoflurane-dexmedetomidine group (P>0.05). But, eye opening following verbal commands and orientation time were significantly shorter postoperatively in patients receiving desflurane-dexmedetomidine than in the other groups (P = 0.001) ( Table 6 ).
In the recovery room, the side effects (nausea and vomiting, shivering) were similar among the groups (P>0.05). Analgesic requirements were similar in all patients (2 patients needed extra analgesic in the sevoflurane-dexmedetomidine group and 4 patients in the desflurane dexmedetomidine and isoflurane-dexmedetomidine groups).
DISCUSSION
Our results showed that constant infusion of dexmedetomidine combined with sevoflurane, desflurane, and isoflurane anesthesia may not provide good control of acute intraoperative blood pressure responses, additional recovery parameters such as eye opening, ability to follow verbal commands, and orientation times were shorter in the desflurane-dexmedetomidine group, as compared with the sevoflurane-dexmedetomidine and isoflurane-dexmedetomidine groups.
Dexmedetomidine has been shown to provide good perioperative hemodynamic stability, sedation, and analgesia. [9] [10] [11] 16 Unlike opioids, midazolam, and propofol, dexmedetomidine does not produce respiratory depression. In healthy volunteers 17 and postoperative surgical ICU patients, 18 dexmedetomidine did not significantly alter arterial pH, PaO 2 , PaCO 2 , respiratory rate, or oxygen saturation. Also, the anesthetic and analgesic sparing effects of dexmedetomidine in particular are well estabilished. [9] [10] [11] [12] [13] In adult patients, dexmedetomidine is generally initiated with a loading infusion of 1 mg/kg over 10 minutes, followed by a maintenance infusion of 0.2 to 0.7 mg/kg/h. We used a loading infusion of 0.5 mg/kg over 10 minutes in all patients. Large concentrations (eg, from a loading dose) or rapid administration (<10 minutes) of dexmedetomidine activate the a-2 receptors on the vascular smooth muscle to initially cause peripheral vasoconstriction, resulting in hypertension and possibly, reflex bradycardia. 19 Yıldız et al 20 concluded that preoperative administration of a single dose of dexmedetomidine resulted in progressive increase in sedation, blunting the hemodynamic responses during laryngoscopy, and reducing opioid and anesthetic requirements. Scheinin et al 11 showed that dexmedetomidine attenuated the cardiovascular responses to laryngoscopy and tracheal intubation. The intense surgical stimuli associated with craniotomy frequently cause sympathetic activation and marked changes in SAP, cerebral blood flow, and intracranial pressure. Dexmedetomidine has been used as an adjuvant agent in neuroanesthesia. 14, 21, 22 Cerebrovascular dilation induced by either isoflurane or sevoflurane is lesser with dexmedetomidine pretreatment in dogs. Perioperative hypertension in neurosurgical patients is associated with intracranial bleeding. The hemodynamic effect of dexmedetomidine results from the peripheral and central mechanism. The initial response to rapid dexmedetomidine infusion may be transient hypertension. In the central nervous system, activation of a-2 receptors leads to a reduction in sympathetic outflow and an increase in vagal activity. 19 In addition, dexmedetomidine may have some as a peripheral ganglionic blocker. 23 Sturaitis et al 24 reported that intraoperative administration of dexmedetomidine (0.3 to 0.8 mg/kg/h) seems to be opioid sparing, with lesser need for antihypertensive medication, and may offer greater hemodynamic stability at incision and emergence during brain tumor resection. In addition, Tanskanen et al 21 received 2 different concentrations of dexmedetomidine infusion (plasma target concentration 0.2 or 0.4 ng/mL) for elective surgery of supratentorial brain tumor. They reported that dexmedetomidine (0.4 ng/mL) blunted the tachycardic response to intubation and the hypertensive response to extubation and differed in HR variability from placebo. Our results showed that hemodynamic variables were similar, but blood pressure and HR increased after tracheal intubation in all groups. Intraoperative hypertension was observed in 4 of 30 patients receiving sevoflurane-dexmedetomidine and in 8 of 30 patients receiving desflurane-dexmedetomidine and in 5 of 30 patients receiving isoflurane-dexmedetomidine and dexmedetomidine infusion failed to completely block the acute hyperdynamic response to craniotomy in our study. The rate of dexmedetomidine infusion was not changed; it was maintained constantly throughout the study period, but the concentration of the inhalation agents was increased in the treatment of hypertension in all groups. We did not use antihypertensive and vasodilator agents on any patients.
The concurrent use of dexmedetomidine with anesthetics, sedatives, hypnotics, and/or opioids is likely to result in an increased central nervous system depressant action, and a reduction in the dosage of one or more agents may be required. Dexmedetomidine has been shown to reduce the MAC of inhalation anesthetics and the need of perioperative fentanyl. 11 Although the infusion of dexmedetomidine was maintained using intraoperative sevoflurane, desflurane and isoflurane, the concentrations were lower throughout the study period than during concentrations of initial anesthetic agents. In the sevoflurane-dexmedetomidine group, the sevoflurane concentration was reduced by a mean of 50% from the induction of anesthesia to dural closure. Similarly, desflurane concentration decreased by approximately 36%, isoflurane concentration reduced by 40%.
After intracranial surgery, inadequate treatment of postoperative pain may result in adverse physical (hypertension, intracranial bleeding) and psychologic outcomes and decreased patient satisfaction. Dexmedetomidine has an analgesic effect or may enhance analgesia, but the analgesic profile of dexmedetomidine has not been fully characterized in humans. We used the same analgesic agents (tramadol plus diclofenac sodium) for all patients. Two patients in group sevoflurane-dex, 4 patients in group desflurane-dex, and 4 patients in group isofluranedex needed rescue analgesic for postoperatively the first 24 hours. The number of the rescue analgesic (diclofenac sodium 75 mg) 2 patients in group sevoflurane-dexmedetomidine, 4 patients in group desflurane-dexmedetomidine, and in group isoflurane-dexmedetomidine for postoperatively the first 24 hours. The concentration of volatile anesthetics is important for brain relaxation. By increasing the concentration the direct vasodilative effect of volatile anesthetics becomes dominant, leading to high cerebral blood flow and volume and to elevated intracranial pressure. Turner et al 25 reported that in a series of 32 patients undergoing supratentorial intracranial surgery, the incidence of tight brain was significantly greater in patients receiving 1 MAC of isoflurane or desflurane than in patients receiving 0.5 MAC of either volatile anesthetic. Our data suggest that the incidence of a tight brain was similar among groups. Greater brain relaxation scores, such as 4 or 5, were not observed.
After classic craniotomies, rapid emergence will allow immediate neurologic examination, early detection, and efficacious management of any potential surgical complication. Volatile anesthetics, such as sevoflurane and desflurane, have a favorable recovery profile because of its low blood/gas partition coefficient. In most studies involving comparisons in emergence time, desflurane shows a definitive advantage over sevoflurane. 26, 27 In addition, Gauthier et al 28 reported that sevoflurane anesthesia provided faster recovery and postoperative neurologic assessment than isoflurane anesthesia in longduration neurosurgical cases. In our study, the time to extubation was similar among groups, and eye opening and response to verbal command were shorter in patients receiving desflurane-dexmedetomidine compared with the other groups. The time to extubation ranged from 2 to 45 minutes for the sevoflurane-dexmedetomidine group, from 1 to 14 minutes for the desflurane-dexmedetomidine group, and from 2 to 28 minutes for the isofluranedexmedetomidine group.
When the respiratory effects of dexmedetomidine and remifentanil were compared in 6 healthy male volunteers, the investigators concluded that although remifentanil infusions decreased respiratory rates and disturbed natural breathing patterns, dexmedetomidine infusions did not cause clinically significant respiratory depression. 18 In our study, there were no differences among groups in postoperative adverse effects of (such as nausea and vomiting, shivering, respiratory depression) studied drugs during emergence from anesthesia or follow-up in PACU.
We conclude that infusion of dexmedetomidine at the doses used in this study is not sufficient to suppress hemodynamic responses, but does decrease the concentration of the needed inhalation agents and supplies brain relaxation and good surgical field exposure conditions without any side effects in patients undergoing supratentorialcraniotomy. Desflurane-dexmedetomidine anesthesia offers faster eye opening, response to verbal commands, and postoperative neurologic assessment than sevoflurane-dexmedetomidine or isoflurane-dexmedetomidine anesthesia.
